Literature DB >> 24078458

Continuously moving table aorto-iliofemoral run-off contrast-enhanced magnetic resonance angiography: image quality analysis in comparison to the multistep acquisition.

Patrick Asbach1, Michael D Meade, Ronald J Sattenberg, Christian Klessen, Alexander Huppertz, Jens O Heidenreich.   

Abstract

BACKGROUND: Optimal vessel contrast is a prerequisite for vascular imaging. Consecutive stationary imaging of multiple fields of view is contrary to the continuous contrast material passage through the vascular tree. A continuous acquisition of a magnetic resonance (MR) sequence might overcome this limitation.
PURPOSE: To investigate the image quality of a continuously moving table (CMT) acquisition compared with the established multistep approach for contrast-enhanced magnetic resonance angiography (CE-MRA) of the aorto-iliofemoral run-off.
MATERIAL AND METHODS: Institutional review board approved this retrospective interindividual study of 60 consecutive patients referred to CE-MRA for peripheral arterial disease. Thirty patients underwent CE-MRA using the routine multistep acquisition and 30 patients were scanned using the CMT technique at 1.5 Tesla. All patients received a fixed contrast dose of 25 mL gadoterate meglumine. A quantitative analysis was performed to assess the relative contrast of 10 vascular segments from the proximal abdominal aorta to the distal calf arteries. A qualitative evaluation of three separate vascular regions (abdomen and pelvis, thighs, and calves) was performed. Two radiologists graded independently arterial vessel conspicuity, venous contamination, presence of artifacts, and diagnostic confidence on a 4-point scale. Overall scan time, including all localizer scans, was recorded. Statistical differences were tested using the Wilcoxon signed-rank test with Bonferroni correction.
RESULTS: No significant differences were found between the continuously moving table acquisition and the multistep acquisition with regard to the relative vascular contrast and the qualitative image criteria. The agreement between both readers was significant (Kendall tau rank correlation coefficient, 0.373). The absolute reader agreement was 71.4%. The mean overall scan time was 12 min 44 s for the CMT protocol and 21 min 41 s for the multistep protocol.
CONCLUSION: Aorto-iliofemoral run-off CE-MRA acquired with CMT technique provides a high image quality equivalent to a multistep technique at an overall scan time reduction of 41.3%.

Entities:  

Keywords:  Adults; MR angiography; arteries; arteriosclerosis; vascular

Mesh:

Substances:

Year:  2013        PMID: 24078458     DOI: 10.1177/0284185113498535

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  3 in total

1.  Evaluation of the Abdominal Aorta and External Iliac Arteries Using Three-Dimensional Time-of-Flight, Three Dimensional Electrocardiograph-Gated Fast Spin-Echo, and Contrast-Enhanced Magnetic Resonance Angiography in Clinically Healthy Cats.

Authors:  Minju Lee; Minjung Ko; Jisoo Ahn; Jiyoung Ahn; Jin Yu; Jinhwa Chang; Sukhoon Oh; Dongwoo Chang
Journal:  Front Vet Sci       Date:  2022-06-09

2.  Noncontrast MR angiography (MRA) of infragenual arteries using flow-sensitive dephasing (FSD)-prepared steady-state free precession (SSFP) at 3.0 Tesla: Comparison with contrast-enhanced MRA.

Authors:  Nan Zhang; Zhaoyang Fan; Nan Luo; Xiaoming Bi; Yike Zhao; Jing An; Jiayi Liu; Zhong Chen; Zhanming Fan; Debiao Li
Journal:  J Magn Reson Imaging       Date:  2015-07-16       Impact factor: 4.813

3.  Image Quality and Stenosis Assessment of Non-Contrast-Enhanced 3-T Magnetic Resonance Angiography in Patients with Peripheral Artery Disease Compared with Contrast-Enhanced Magnetic Resonance Angiography and Digital Subtraction Angiography.

Authors:  Jiayi Liu; Nan Zhang; Zhaoyang Fan; Nan Luo; Yike Zhao; Xiaoming Bi; Jing An; Zhong Chen; Dongting Liu; Zhaoying Wen; Zhanming Fan; Debiao Li
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.